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Abstract
Introduction: It is not clear whether high mammographic density (MD) is equally associated with all subtypes
of breast cancer (BC). We investigated the association between MD and subsequent BC, considering
invasiveness, means of detection, pathologic subtype, and the time elapsed since mammographic exploration
and BC diagnosis.
Methods: BC cases occurring in the population of women who attended screening from 1997 through 2004 in
Navarre, a Spanish region with a fully consolidated screening program, were identified via record linkage with the
Navarre Cancer Registry (n = 1,172). Information was extracted from the records of their first attendance at
screening in that period. For each case, we randomly selected four controls, matched by screening round, year of
birth, and place of residence. Cases were classified according to invasiveness (ductal carcinoma in situ (DCIS) versus
invasive tumors), pathologic subtype (considering hormonal receptors and HER2), and type of diagnosis (screen-
detected versus interval cases). MD was evaluated by a single, experienced radiologist by using a semiquantitative
scale. Data on BC risk factors were obtained by the screening program in the corresponding round. The association
between MD and tumor subtype was assessed by using conditional logistic regression.
Results: MD was clearly associated with subsequent BC. The odds ratio (OR) for the highest MD category (MD >75%)
compared with the reference category (MD <10%) was similar for DCIS (OR = 3.47; 95% CI = 1.46 to 8.27) and invasive
tumors (OR = 2.95; 95% CI = 2.01 to 4.35). The excess risk was particularly high for interval cases (OR = 7.72; 95% CI =
4.02 to 14.81) in comparison with screened detected tumors (OR = 2.17; 95% CI = 1.40 to 3.36). Sensitivity analyses
excluding interval cases diagnosed in the first year after MD assessment or immediately after an early recall to screening
yielded similar results. No differences were seen regarding pathologic subtypes. The excess risk associated with MD
persisted for at least 7 to 8 years after mammographic exploration.
Conclusions: Our results confirm that MD is an important risk factor for all types of breast cancer. High breast
density strongly increases the risk of developing an interval tumor, and this excess risk is not completely explained
by a possible masking effect.
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Introduction
In Spain, a European country with moderate incidence of
breast cancer (BC), all the Autonomous Regions intro-
duced population-based BC screening programs during the
1990s, with full coverage being attained by the beginning
of this century [1]. Although regional differences exist,
these programs have been well received, and participation
rates are usually high (mean overall participation of 67%)
[1]. Indeed, screening has had a clear influence on Spanish
BC trends [2]. Currently, all Spanish women aged 50 to 69
or 45 to 69 years, depending on the region, are invited to
have a mammogram every other year, amounting to a total
catchment population of more than 5 million.
Mammograms are useful not only from a diagnostic
point of view. Mammographic density (MD), or the per-
centage of the mammogram occupied by radiologically
dense tissue, is a well-established BC risk factor [3]. MD
is highly heritable [4] but is also influenced by classic
BC determinants, such as parity, benign breast disease,
and combined hormonal therapy [5-7]. Even though the
biologic basis of the association between MD and BC is
not fully understood, breast density is increasingly used
as a phenotype risk marker [5].
At present, screening guidelines, both in Europe and
in the United States, recommend mammography every
2 years [8,9]. In practice, family history and benign
pathology of the breast are taken into account to recom-
mend early recalls. A recent study proposed the inclusion
of MD in a personalized scheme for screening follow-up
[10]. Before incorporating MD assessment into the deci-
sion algorithm for cancer prevention, it is essential to
confirm its ability to predict all BC subtypes, and more-
aggressive tumors in particular, something that has not
been fully established [5]. Breast density impairs tumor
detection, increasing the probability of false-negative
results [11,12]. As regards tumor subtypes, whereas some
cohort and case-control studies have examined the asso-
ciation between high MD and BC according to type of
tumor, many of these included a low number of cases,
and their results are not homogeneous [13-19].
This article relies on data from a population-based
case-control study conducted in the context of the
Navarre Breast Cancer Screening Program (NBCSP) to
evaluate the association between MD and subsequent
risk of BC, according to tumor invasiveness, pathologic
subtype, and means of detection.
Materials and methods
Study population
The NBCSP, the first population-based screening pro-
gram implemented in Spain, was initiated in 1990 and
achieved full coverage by 1992 [1]. Whereas the NBCSP
initially targeted women aged 45 to 65 years residing in
the Northern Spanish province of Navarre, in 1998, the
age range was extended to include women aged up to 69
years (77,455 female inhabitants aged 45 to 69 years in
2001). In general, women are screened every 2 years, fol-
lowing European guideline recommendations [8]. The
overall participation rate and adherence to the NBCSP
during the period from 1990 to 2004 were very high (88%
and 97%, respectively). A detailed description of the pro-
gram can be consulted elsewhere [20].
The current case-control study is based on the popula-
tion of women who attended the NBCSP at least once
between the fourth (September 1996 to August 1998)
and seventh (September 2002 to August 2004) screening
rounds. These women were prospectively followed up for
BC occurrence from the date of their first NBCSP scan in
the study period, until December 31, 2005. BC cases,
whether invasive tumors or ductal carcinomas in situ
(DCISs), were ascertained through linkage with the popu-
lation-based Navarre Cancer Registry. To ensure comple-
teness, follow-up was restricted to year-end 2005, the last
complete year available when the study was designed.
During follow-up, in total, 3,003 new BC cases were
registered among women living in Navarre: 2,259
occurred in women who had participated in the screen-
ing program, and 1,461 corresponded to women who had
attended screening at least once between the fourth and
seventh rounds. Cases diagnosed during the first 6
months after their first contact with the NBCSP between
the fourth and seventh rounds (baseline screening round)
were considered prevalent and therefore excluded (n =
289). For the remaining 1,172 incident cases, the average
time elapsed from baseline to date of BC diagnosis was
4.3 years (interquartile range, 2.1 to 5.9 years).
Case and control selection
We included all 1,172 incident cases of invasive BC or
DCIS diagnosed in the period between 6 months after
baseline (first NBCSP attendance between the fourth and
the seventh rounds) and December 31, 2005. All cases
were classified on the basis of the means of detection as
screen-detected cases, interval cases, or external cases,
with the latter group comprising cases diagnosed in
women older than 69 years (NBCSP upper age limit) plus
those registered in women who had prematurely with-
drawn from the program. Based on pathology reports,
invasive BC cases were further classified as estrogen and/
or progesterone receptor-positive and HER2-negative
tumors, HER2-positive tumors, or triple-negative tumors.
In total, 4,688 controls were randomly selected (case-
to-control ratio, 1:4) from all women in the source popu-
lation who remained disease free at the end of follow-up.
Controls were frequently matched to cases by screening
round, single year of birth, and place of residence (single
towns with more than 5,000 inhabitants or aggregated
rural areas comprising smaller towns).
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Mammographic density and other risk factors
Information for cases and their matched controls was
obtained from mammograms and epidemiologic question-
naires collected by the NBCSP at the baseline screening
round, defined as the first screening attendance of the cor-
responding case between the fourth (September 1996 to
August 1998) and the seventh (September 2002 to August
2004) rounds of the NBCSP. Breast density was assessed
from the mediolateral oblique mammographic projection
of the left breast. This was chosen because it was the only
projection available during the fourth NBCSP round for
previous participants. MD was visually assessed by a single,
experienced radiologist blinded to case/control status, by
using the Boyd semiquantitative scale with the following
categories of density: 0; <10%; 10% to 25%; 25% to 50%;
50% to 75%; and >75%. The radiologist had been pre-
viously trained in using a transparent grid template to
quantify the total breast area and the area composed of
dense tissue. After the training process, mediolateral obli-
que-view mammograms from 100 randomly selected dis-
ease-free women were read twice in different random
orders to assess intrarater reliability, which proved to be
substantially high (quadratic-weighted kappa: 0.93; 95% CI
= 0.89 to 0.96). Very good agreement was found between
MD measurements drawn from mediolateral oblique and
craniocaudal mammographic projections in the same ran-
dom sample of 100 women (quadratic-weighted kappa,
0.92; 95% CI = 0.88 to 0.94). Because of the small number
of women with a MD of 0, the first two categories were
collapsed and used in all analysis as the reference group
(MD = 0 to 10%).
Baseline information on age at menarche, parity, age
at first live birth, menopausal status, age at menopause,
number of first-degree and second-degree relatives with
BC, age of affected relatives at diagnosis, previous breast
biopsy, and current use of hormone replacement therapy
was obtained from structured questionnaires adminis-
tered by trained interviewers.
Statistical analysis
Because the number of cases in each stratum obtained by
cross-classifying the three matching factors was typically
sparse, the association between MD plus other baseline
explanatory variables and BC risk was evaluated by using
conditional logistic regression models to account fully for
the matched structure of the data. Crude odds ratios
(adjusted solely for the matching variables) and adjusted
odds ratios (considering all risk factors associated with BC
in crude analyses) were obtained. Because of the small
number of women with low density, the two first cate-
gories of MD were combined and used as the reference
group. The multivariate model was separately fitted for
DCIS and invasive tumors. The same model was used to
assess the association between MD and other explanatory
variables, and screen-detected and interval cases. The
number of cases detected among women who had with-
drawn from the program was too small for these to be
deemed a separate group.
The stability of the association between MD and BC
was explored, taking into account the time span between
the date of baseline exploration (that is, the moment
when MD and the remaining variables were assessed)
and the date of diagnosis, considering three periods (that
is, less than 3 years, 3 to 6 years, and 6 years and longer).
Furthermore, to test the consistency of the excess risk
associated with high MD, subgroup analyses were con-
ducted by including interaction terms for MD density
(four categories: 0 to 10%, 10% to 25%, 25% to 50%, and
>50%) with the other explanatory variables.
Finally, with the information provided by pathology
records, the final model was separately fitted for each
pathologic subtype, considering the previously men-
tioned four categories of MD. To test whether the asso-
ciation differed by pathologic subtype, a multinomial
logistic model was used, adjusting for screening round,
age at screening, and the remaining variables. The likeli-
hood ratio test was used to compare a model with sepa-
rate MD slopes for each tumor type with a model
constrained to have a common slope [21].
All statistical analyses were performed by using the
STATA version 12.0 software program (Stata Corp, College
Station, TX, USA).
Ethical considerations
The study was approved by the Ethics Committee of the
Carlos III Institute of Health (Comité de Ética de la
Investigación y De Bienestar Animal CEIyBA ISCIII) and
conducted in compliance with the Helsinki Declaration.
Specific patient informed consent was not required for
this study, because all women consented to participate in
the NBCSP, and the program was authorized to collect
and use health and clinical information from screening
participants for evaluation and scientific research.
Results
The study included 1,172 incident breast cancer cases,
made up of 184 DCIS and 988 invasive tumors, and 4,688
matched controls. Seventy-five percent of cases were diag-
nosed directly by the NBCSP (875), 251 (21%) were inter-
val cases, and only 46 (4%) were observed in women who
had withdrawn from the program. In most instances, base-
line exploration corresponded to the fourth round (84%).
Average age at exploration was 53 years. Around one third
of these women were premenopausal (Table 1). Compared
with controls, cases had a higher proportion of nulliparous
women (19% versus 13%), family history of BC (19% ver-
sus 14%), particularly in terms of first-degree relatives
(10% versus 6%), and a higher frequency of previous
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Table 1 Baseline characteristics of cases and controls, and odds ratios for total breast cancer in the NBCSP
case-control study
Characteristic No. of controls (%) No. of breast cancer cases (%) Odds ratioa(95% CI) P valueb
Screening round (baseline exploration)
September 1996 to August 1998 3,948 (84.1) 987 (84.1)
September 1998 to August 2000 408 (8.7) 102 (8.7)
September 2000 to August 2002 224 (4.8) 56 (4.8)
September 2002 to August 2004 108 (2.3) 27 (2.3)
Age at baseline exploration (years)
<50 1,733 (37.0) 433 (37.0)
50-54 986 (21.0) 245 (20.9)
55-59 897 (19.1) 228 (19.5)
60-64 870 (18.6) 217 (18.5)
≥65 202 (4.3) 49 (4.2)
Age at menarche (years) 0.357c
≥15 724 (15.5) 161 (13.7) 0.95 (0.77-1.18)
14 1,243 (26.5) 290 (24.7) 1.00 (reference)
13 1,281 (27.3) 363 (31.0) 1.22 (1.03-1.45)
12 867 (18.5) 225 (19.2) 1.11 (0.92-1.35)
<12 569 (12.1) 132 (11.3) 1.00 (0.79-1.25)
Unknown 4 (0.1) 1 (0.1)
Age at first live birth (years) <0.001
<20 102 (2.2) 13 (1.1) 0.51 (0.28-0.91)
20-24 1,441 (30.7) 293 (25.0) 0.81 (0.68-0.95)
25-29 1,823 (38.9) 457 (39.0) 1.00 (reference)
30-34 522 (11.1) 134 (11.4) 1.03 (0.83-1.28)
≥35 175 (3.7) 57 (4.9) 1.31 (0.95-1.80)
Nulliparous 625 (13.3) 218 (18.6) 1.41 (1.17-1.70)
Age at menopause (years) 0.001
≤45 777 (16.6) 147 (12.5) 1.00 (reference)
46-50 1,244 (26.5) 298 (25.4) 1.25 (1.01-1.56)
>50 1,035 (22.1) 293 (25.0) 1.48 (1.17-1.87)
Premenopausal 1,631 (34.8) 434 (37.0) 1.44 (1.14-1.83)
Unknown 1 (0.0) 0 (0.0)
Family history of breast cancer <0.001
None 4,075 (86.9) 945 (80.6) 1.00 (reference)
Second-degree relative 327 (7.0) 109 (9.3) 1.43 (1.14-1.80)
First-degree relative ≥50 years 172 (3.7) 64 (5.5) 1.61 (1.19-2.16)
First-degree relative <50 years 114 (2.4) 54 (4.6) 2.06 (1.48-2.88)
Previous breast biopsy <0.001
No 4,281 (91.3) 1,001 (85.4) 1.00 (reference)
Yes 407 (8.7) 171 (14.6) 1.82 (1.50-2.22)
Use of hormone replacement therapy 0.602
No 4,208 (89.8) 1,046 (89.2) 1.00 (reference)
Yes 480 (10.2) 126 (10.8) 1.06 (0.86-1.31)
Mammographic density (%) <0.001c
0-10 1,711 (36.5) 263 (22.4) 1.00 (reference)
11-25 1,136 (24.3) 244 (20.8) 1.52 (1.25-1.85)
26-50 1,158 (24.8) 375 (32.0) 2.47 (2.05-2.98)
51-75 529 (11.3) 215 (18.3) 3.27 (2.62-4.09)
>75 135 (2.9) 59 (5.0) 3.74 (2.63-5.32)
Unknown 19 (0.4) 16 (1.4)
aOdds ratios for total breast cancer and 95% confidence intervals (CIs) obtained from conditional logistic regression models that accounted for the matching
factors (screening round, year of birth, and place of residence). bP values for homogeneity of breast cancer risk across categories, except in the case of age at
menarche and mammographic density. cP values for linear trend using an ordinal variable
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biopsies (15% versus 9%). However, use of hormonal repla-
cement treatment was similar in both groups (11% versus
10%). MD was higher among cases, with 23% of them
being in the two highest categories (MD >50%), as opposed
to 14% of controls. At the other extreme, 37% of controls
had less than 10% of dense tissue versus 22% among cases
(Table 1).
Table 1 also shows crude odds ratios (ORs) and 95%
confidence intervals (95% CIs) for the explanatory vari-
ables. Linear trend tests were obtained, including the cate-
goric variable as a continuous term. Most of the risk
factors considered were associated with breast cancer.
However, neither age at menarche nor use of hormonal
replacement therapy at the date of exploration modified
BC risk in our study (Table 1). As regards family history of
BC, a distinction was drawn among first-degree relatives
according to their age at diagnosis, taking age 50 years as
cutoff. The highest risk was observed among women with
first-degree relatives aged younger than 50 years at diagno-
sis (OR = 2.06; 95% CI = 1.48 to 2.88). MD, our exposure
of interest, showed a clear positive association with BC
(P-trend <0.001). The two highest categories of density
(>50%) registered ORs of >3, compared with the reference
category (<10%) (OR = 3.27; 95% CI = 2.62 to 4.09 for
MD = 50% to 75%; and OR = 3.74; 95% CI = 2.63 to 5.32
for MD >75%).
Table 2 shows the results of the multivariate analysis
both overall, for all cases combined, and for cases stratified
by tumor invasiveness (DCIS or invasive cancer). Adjusting
for other risk factors had a modest effect on the association
between MD and BC. ORs were similar for DCIS and inva-
sive tumors (ORDCIS = 3.47; 95% CI = 1.46 to 8.27; and
ORinvasive = 2.78; 95% CI = 1.87 to 4.06 for MD >75%), and
a clear dose-response with increasing MD was observed in
both instances. Table 3 shows the results obtained with the
same multivariate model for screen-detected BC cases and
interval tumors. ORs were particularly high in the two
highest categories of density for interval tumors (OR =
4.25; 95% CI = 2.53 to 7.14, and OR = 7.72l; 95% CI = 4.02
to 14.81 for MD of 50% to 75% and >75%, respectively). To
avoid a possible masking effect of MD, which might pro-
duce a false-negative result at screening, the analysis was
repeated by taking only case-control sets with interval
cases diagnosed more than 12 months after mammo-
graphic assessment (225 cases). The results were very simi-
lar (OR = 3.93; 95% CI = 2.26 to 6.82 for the 50% to 75%
category, and OR = 7.62; 95% CI = 3.82 to 15.19 for MD
>75%). Furthermore, the exclusion of interval cases
observed after an exploration that was motivated by an
early recall (21 cases), yielded similar results (OR = 4.22;
95% CI = 2.47 to 7.21 for MD 50% to 75%; and OR = 7.93;
95% CI = 4.00 to 15.70 for MD >75%).
The excess risk associated with higher density
appeared to remain stable for at least the first 7 to 8
years after mammographic assessment (Figure 1). The
relative linear increase in risk per category of density
was similar in the three groups considered (OR = 1.40;
95% CI = 1.25 to 1.56 for tumors diagnosed 6 months
to 3 years after exploration; OR = 1.41; 95% CI = 1.27
to 1.56 for those diagnosed between 3 and 6 years after
exploration; and OR = 1.33; 95% CI = 1.20 to 1.48 for
cancers detected 6 or more years after exploration).
Figure 2 depicts the effect of high MD per category of
other explanatory variables. Given the small number of
subjects in some strata, the two extreme categories of den-
sity were collapsed at both sides. The figure shows the
ORs for the highest MD (>50%) versus the reference cate-
gory (0 to 10%), adjusted for the factors included in the
multivariate model (Tables 2 and 3). With few exceptions,
the effect was very consistent across all strata. The associa-
tion was stronger in younger women and particularly
among those who were premenopausal at the date of
exploration (P value for interaction = 0.008). Given this
different effect in pre-and postmenopausal women, the
final model was separately fitted in these two groups (see
Additional file 1, Table S1). In postmenopausal women,
the ORs for the two highest MD categories were 2.10
(95%CI = 1.52 to 2.89) for a density of 50% to 75% and
1.98 (95% CI = 1.04 to 3.76) for MD >75%. The corre-
sponding estimators in premenopausal women were 4.88
(95% CI = 2.97 to 8.01) and 5.13 (95% CI = 2.83 to 9.30).
Information on hormonal receptors and HER2 status
was available for 86% of invasive cases (N = 834) but
not for a substantial proportion of DCIS. Table 4 shows
the effect of MD and the remaining explanatory vari-
ables included in the final model, according to patholo-
gic subtype of invasive BC. MD was similarly associated
with all pathologic subtypes (P value of heterogeneity =
0.380), although ORs were somewhat higher for triple-
negative tumors (for MD >50% versus MD = 0 to 10%:
OR = 3.15; 95% CI = 1.26 to 7.84), intermediate for
tumors with hormonal receptors and no expression of
HER2 (OR = 2.60; 95% CI = 1.95 to 3.45), and weaker
for HER2+ tumors (OR = 1.68; 95% CI = 0.83 to 3.41).
This analysis was repeated by subdividing HER2+
tumors according to the presence/absence of hormonal
receptors (65 and 46 cases, respectively), with similar
results being obtained in both groups (data not shown).
Discussion
In this population-based study of regularly screened
women, MD displayed a strong and consistent associa-
tion with subsequent BC. A high proportion of dense
tissue increased the risk of DCIS and invasive BC. MD
was associated with screen-detected tumors, but the
excess risk was substantially higher for interval cases.
Finally, MD proved to be an important risk factor for all
pathologic subgroups.
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Previous studies have suggested that MD is associated
mainly with tumors with hormonal receptors [15-17],
whereas others, in agreement with our results, reported
a similar or even stronger association with ER-/PR-
tumors [13,14,18,19]. Overexpression of HER2 was eval-
uated in a few studies, although their results, like ours,
confirm that high MD also increases the risk of HER2+
tumors [13,14,18]. Finally, the two studies that furnished
information on triple-negative tumors also found a
strong association between MD and this pathologic sub-
type [13,18].
Risk estimates were particularly high for interval cases.
According to our results, interval tumors are 7 times
more frequent among women with MD >75% than
among those with MD <10%. A previous study in the
United States found relative risks similar to those
reported here for the highest MD category [11].
Although this strong association can be partly explained
by the increased difficulty of tumor detection in highly
dense breasts, it may also be related to enhanced
proliferation under the stimulus of collagen and stromal
growth factors [22]. Indeed, less-favorable subtypes are
more frequently found among interval cases [23,24]. In
our study, triple-negative and HER+ tumors accounted
for 6% and 12% of all screen-detected invasive tumors,
respectively, whereas 14% of interval cases were triple
negative, and up to 18% were HER2+. Interval tumors
tend to be more aggressive and have a poorer prognosis
[25].
MD is influenced by classic BC risk factors, such as
family history, reproductive factors, benign breast dis-
ease, and others [5,6,26]. According to our results, how-
ever, adjusting for family history and other possible
confounders slightly altered the estimated effect. Never-
theless, information on our participants’ body mass
index (BMI) was not available and could not be taken
into account. BMI is a well-established risk factor for
postmenopausal BC and is inversely associated with
MD, because fat is also stored in the breast, reducing
the relative amount of dense tissue. It has been shown
Table 2 Association between mammographic density and other selected risk factors, and risk of total, invasive, and in
situ breast cancer in the NBCSP case-control study
Total breast cancer Invasive breast cancer Ductal carcinoma in situ














Age at first live birthb
5-year increase 4,048 (86.8) 940 (81.3) 1.12 (1.02-1.22) 795 (81.8) 1.10 (1.00-1.21) 145 (78.8) 1.19 (0.97-1.46)
Nulliparous 618 (13.2) 216 (18.7) 1.34 (1.12-1.61) 177 (18.2) 1.30 (1.06-1.58) 39 (21.2) 1.58 (1.04-2.40)
Age at menopausec
5-year increase 3,040 (65.2) 728 (63.0) 1.18 (1.06-1.30) 619 (63.7) 1.17 (1.05-1.30) 109 (59.2) 1.20 (0.92-1.55)
Premenopausal 1,626 (34.8) 428 (37.0) 1.14 (0.93-1.41) 353 (36.3) 1.20 (0.95-1.51) 75 (40.8) 0.96 (0.59-1.55)
Family history of breast
cancer
None 4,055 (86.9) 932 (80.6) 1.00 (reference) 790 (81.3) 1.00 (reference) 142 (77.2) 1.00 (reference)
Second-degree
relative
325 (7.0) 107 (9.3) 1.39 (1.10-1.75) 89 (9.2) 1.39 (1.08-1.79) 18 (9.8) 1.42 (0.83-2.43)
First-degree relative
≥50 years
172 (3.7) 64 (5.5) 1.46 (1.08-1.98) 49 (5.0) 1.33 (0.95-1.87) 15 (8.2) 2.11 (1.13-3.94)
First-degree relative
<50 years
114 (2.4) 53 (4.6) 1.90 (1.35-2.68) 44 (4.5) 2.00 (1.38-2.91) 9 (4.9) 1.63 (0.77-3.47)
Previous breast biopsy
No 4,263 (91.4) 986 (85.3) 1.00 (reference) 826 (85.0) 1.00 (reference) 160 (87.0) 1.00 (reference)
Yes 403 (8.6) 170 (14.7) 1.57 (1.28-1.92) 146 (15.0) 1.68 (1.36-2.08) 24 (13.0) 1.11 (0.68-1.83)
Mammographic density (%)
0-10 1,710 (36.6) 263 (22.7) 1.00 (reference) 233 (24.0) 1.00 (reference) 30 (16.3) 1.00 (reference)
11-25 1,136 (24.3) 244 (21.1) 1.43 (1.18-1.74) 206 (21.2) 1.39 (1.12-1.71) 38 (20.7) 1.65 (1.01-2.83)
26-50 1,157 (24.8) 375 (32.4) 2.24 (1.85-2.71) 319 (32.8) 2.18 (1.78-2.68) 56 (30.4) 2.65 (1.60-4.40)
51-75 528 (11.3) 215 (18.6) 2.76 (2.19-3.48) 164 (16.9) 2.38 (1.85-3.06) 51 (27.7) 5.60 (3.24-9.67)
>75 135 (2.9) 59 (5.1) 3.06 (2.14-4.40) 50 (5.1) 2.95 (2.01-4.35) 9 (4.9) 3.47 (1.46-8.27)
P value for trendd <0.001 <0.001 < 0.001
aOdds ratios and 95% confidence intervals (CIs) for total, invasive, and in situ breast cancer obtained from separate multivariate conditional logistic regression
models adjusted for all risk factors shown in the table. bAdjusted odds ratios per 5-year increase in age at first live birth among parous women, as well as for
nulliparous women compared with women having their first live birth at 25 years. cAdjusted odds ratios per 5-year increase in age at menopause among
postmenopausal women, as well as for premenopausal women compared with women having their menopause at 45 years. dP values for linear trend by using
an ordinal variable with values 1 through 6 across successive categories of mammographic density.
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that the adjustment for BMI increases the magnitude of
the MD effect [27], and that MD reverses the negative
association between BMI and BC in premenopausal
women [28]. In our case, failure to adjust for BMI
would imply an underestimation of the MD effect and
explain why relative risks here are smaller than those
reported by other studies [3]. This underestimation
would be more important in postmenopausal women,
and may partly explain why the association between MD
and breast cancer was stronger in the premenopausal
group. However, a recent meta-analysis reviewing BC
risk factors in women in their 40s confirmed that MD is
one of the strongest determinants among these women
[29]. The underestimation would also be more pro-
nounced for ER-positive tumors, the subgroup that
shows a stronger association with BMI [30]. The lack of
information regarding alcohol intake may also be con-
sidered a limitation. However, its potential effect as a
confounder would be very limited in our case, taking
into account the patterns of consumption of these
women. A previous study in screening participants in
Spain showed that 42% of these women did not con-
sume alcohol, and 72% of those who did reported an
intake lower than 10 g/day [31]. This study found a
modest association between alcohol intake and MD only
in postmenopausal women [31], far too small to explain
the strong association between MD and BC reported
here. In spite of the previously mentioned considera-
tions, the stability of risk estimates in subgroup analyses,
the association between MD and all breast cancer sub-
types, and the persistence of its effect for at least 7 to 8
years (according to our and others’ findings [12]), would
support the use of MD as a risk marker to be consid-
ered when seeking to adapt screening recommendations.
Mammography screening should maintain a delicate
balance between benefit and risk [32]. One in five Span-
ish women regularly screened would receive a false-posi-
tive result, resulting in unnecessary reexaminations and
invasive procedures [33]. Overdiagnosis, with ensuing
overtreatment, is a particular concern. A recent study
has shown that, not only DCIS, but also some invasive
screen-detected tumors might spontaneously regress
[34]. Conversely, interval tumors are an important indi-
cator of the potential effectiveness of screening.
Although interval cases include false-negative results,
most of these (65% to 75%) are fast-growing cancers
Table 3 Association between mammographic density and other selected risk factors, and risk of total breast cancer
stratified by means of detection in the NBCSP case-control study
Screen-detected breast cancer Interval breast cancer
Baseline risk factor No. of controls (%) No. of cases (%) Odds ratioa(95% CI) No. of cases (%) Odds ratioa(95% CI)
Age at first live birthb
5-year increase 4,048 (86.8) 705 (81.0) 1.11 (1.00-1.23) 202 (84.2) 1.17 (0.98-1.41)
Nulliparous 618 (13.2) 165 (19.0) 1.38 (1.12-1.70) 38 (15.8) 1.14 (0.77-1.70)
Age at menopausec
5-year increase 3,040 (65.2) 573 (65.9) 1.17 (1.05-1.31) 121 (50.4) 1.18 (0.92-1.50)
Premenopausal 1,626 (34.8) 297 (34.1) 1.04 (0.82-1.32) 119 (49.6) 1.56 (1.02-2.38)
Family history of breast cancer
None 4,055 (86.9) 712 (81.8) 1.00 (reference) 184 (76.7) 1.00 (reference)
Second-degree relative 325 (7.0) 75 (8.6) 1.24 (0.95-1.63) 28 (11.7) 1.83 (1.16-2.87)
First-degree relative ≥50 years 172 (3.7) 49 (5.6) 1.49 (1.06-2.10) 13 (5.4) 1.55 (0.80-2.97)
First-degree relative <50 years 114 (2.4) 34 (3.9) 1.57 (1.05-2.36) 15 (6.3) 2.83 (1.53-5.22)
Previous breast biopsy
No 4,263 (91.4) 747 (85.9) 1.00 (reference) 200 (83.3) 1.00 (reference)
Yes 403 (8.6) 123 (14.1) 1.48 (1.18-1.86) 40 (16.7) 1.99 (1.34-2.96)
Mammographic density (%)
0-10 1,710 (36.6) 220 (25.3) 1.00 (reference) 32 (13.3) 1.00 (reference)
11-25 1,136 (24.3) 188 (21.6) 1.30 (1.05-1.62) 46 (19.2) 1.95 (1.20-3.17)
26-50 1,157 (24.8) 273 (31.4) 2.00 (1.62-2.47) 87 (36.3) 3.54 (2.24-5.60)
51-75 528 (11.3) 155 (17.8) 2.45 (1.89-3.17) 52 (21.7) 4.25 (2.53-7.14)
>75 135 (2.9) 34 (3.9) 2.17 (1.40-3.36) 23 (9.6) 7.72 (4.02-14.81)
P value for trendd <0.001 < 0.001
aOdds ratios and 95% confidence intervals (CIs) for screen-detected and interval breast cancer obtained from separate multivariate conditional logistic regression
models adjusted for all risk factors shown in the table. bAdjusted odds ratios per 5-year increase in age at first live birth among parous women, as well as for
nulliparous women compared with women having their first live birth at 25 years. cAdjusted odds ratios per 5-year increase in age at menopause among
postmenopausal women, as well as for premenopausal women compared with women having their menopause at 45 years. dP values for linear trend by using
an ordinal variable with values 1 through 6 across successive categories of mammographic density.
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Figure 1 Association between mammographic density and breast cancer according to time elapsed between baseline screening
exploration and tumor diagnosis. Odds ratios and 95% confidence intervals adjusted for age, age at first live birth, menopausal status and
age at menopause, familial history of breast cancer, and history of previous biopsies.
Figure 2 Association between mammographic density (MD) and breast cancer. Odds ratios and 95% confidence intervals for MD >50%
compared with MD = 0 to 10% per category of other explanatory variables. Estimators are adjusted for age, age at first live-birth, menopausal
status and age at menopause, familial history of breast cancer, and history of previous biopsies.
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that were not visible in the previous mammogram
[23,24,35]. In this respect, it seems important to identify
the small group of high-risk women who may benefit from
an ad hoc follow-up scheme [36]. A recent study in the
United States corroborates the fact that, as age or breast
density increased, many fewer women needed to be
screened to prevent one death of breast cancer [10]. The
authors propose different personalized screening schemes
according to MD and the presence/absence of established
risk factors [10], but this option should be tested before
being transferred to on-going screening programs. To
maximize the impact on mortality while time avoiding
screening side effects, such programs should follow estab-
lished protocols until new schemes prove to be equally or
more effective.
This study, set in the context of a fully consolidated
population-based screening program with a high participa-
tion rate, confirms the strong relation between MD and
BC, regardless of invasiveness, pathologic subtype, and
means of diagnosis. To interpret our results, however,
some limitations should be borne in mind. First, MD was
visually assessed, implying a certain degree of subjectivity.
Computer-assisted methods might be a better choice, but
they are not exempt from subjectivity, require specific
training, and are labor intensive and difficult to incorpo-
rate into mass screening [37]. Second, as mentioned ear-
lier, BMI was not available and could not be taken into
account, something that translates into an underestima-
tion of the real excess risk associated with MD. Last,
tumor classification was based on data registered in the
corresponding pathologic records at the two hospitals car-
ing for breast cancer patients in the region. A certain
degree of misclassification cannot be ruled out.
Conclusions
High MD was associated with all pathologic subgroups of
breast cancer. The excess risk persisted at least 7 to 8
years after mammographic assessment. Our results con-
firm that MD is an important risk factor regardless breast
cancer subtype and the method of detection. The risk of
Table 4 Association between mammographic density and other selected risk factors, and risk of invasive breast cancer




HER2-positive breast cancer Hormone receptor-negative
and HER2-negative breast
cancer














Age at first live birthb
5-year increase 4,048 (86.8) 534 (82.0) 1.15 (1.02-1.28) 94 (84.7) 1.13 (0.88-1.44) 57 (79.2) 0.72 (0.49-1.06)
Nulliparous 618 (13.2) 117 (18.0) 1.31 (1.03-1.66) 17 (15.3) 1.04 (0.58-1.86) 15 (20.8) 1.23 (0.63-2.39)
Age at menopausec
5-year increase 3,040 (65.2) 415 (63.8) 1.11 (0.98-1.27) 62 (55.9) 1.36 (0.97-0.69) 50 (69.4) 1.01 (0.68-1.51)
Premenopausal 1,626 (34.8) 236 (36.3) 1.15 (0.87-1.51) 49 (44.1) 1.29 (0.69-2.43) 22 (30.6) 0.88 (0.40-1.92)
Family history of breast
cancer
None 4,055 (86.9) 538 (82.6) 1.00 (reference) 90 (81.1) 1.00 (reference) 54 (75.0) 1.00 (reference)
Second-degree relative 325 (7.0) 66 (10.1) 1.46 (1.09-1.95) 11 (9.9) 1.51 (0.76-3.01) 4 (5.6) 0.67 (0.22-2.01)
First-degree relative ≥
50 years
172 (3.7) 29 (4.5) 1.13 (0.74-1.73) 4 (3.6) 1.26 (0.43-3.68) 8 (11.1) 2.28 (0.94-5.48)
First-degree relative <
50 years
114 (2.4) 18 (2.8) 1.10 (0.65-1.87) 6 (5.4) 2.82 (1.10-7.20) 6 (8.3) 3.59 (1.25-10.33)
Previous breast biopsy
No 4,263 (91.4) 547 (84.0) 1.00 (reference) 98 (88.3) 1.00 (reference) 59 (81.9) 1.00
Yes 403 (8.6) 104 (16.0) 1.80 (1.40-1.32) 13 (11.7) 1.39 (0.74-2.60) 13 (18.1) 1.84 (0.90-3.76)
Mammographic density (%)
0-10 1,710 (36.6) 154 (23.7) 1.00 (reference) 24 (21.6) 1.00 (reference) 16 (22.2) 1.00 (reference)
11-25 1,136 (24.3) 143 (22.0) 1.44 (1.12-1. 85) 27 (24.3) 1.58 (0.88-2.82) 13 (18.1) 1.27 (0.56-2.89)
26-50 1,157 (24.8) 202 (31.0) 2.01 (1.57-2. 57) 42 (37.8) 2.61 (1.47-4.63) 29 (40.3) 3.18 (1.54-6.55)
> 50 663 (14.2) 152 (23.3) 2.60 (1.95-3. 45) 18 (16.2) 1.68 (0.83-3.41) 14 (19.4) 3.15 (1.26-7.84)
P value for trendd <0.001 0.024 0.001
aOdds ratios and 95% confidence intervals (CIs) for pathologic subtypes of invasive breast cancer obtained from separate multivariate conditional logistic
regression models adjusted for all risk factors shown in the table. bAdjusted odds ratios per 5-year increase in age at first live birth among parous women, as
well as for nulliparous women compared with women having their first live birth at 25 years. cAdjusted odds ratios per 5-year increase in age at menopause
among postmenopausal women, as well as for premenopausal women compared with women having their menopause at 45 years. dP values for linear trend
using an ordinal variable with values 1 through 4 across successive categories of mammographic density.
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developing an interval cancer is higher in women with
dense breasts, and their excess risk is not explained by a
masking effect. The introduction of digital mammo-
graphic devices and the development of integrated soft-
ware to estimate MD will help overcome the drawbacks
of currently established methods [37] and facilitate the
incorporation of MD assessment in the routine of breast
cancer screening.
Additional material
Additional file 1: Association between mammographic density and
other selected risk factors, and risk of total breast cancer stratified
by menopausal status. Results from the multivariate model separately
fitted in pre-and postmenopausal women.
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